175 related articles for article (PubMed ID: 15654274)
21. Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy.
Gurney H; Kefford R; Stuart-Harris R
Lancet; 1989 Jul; 2(8657):241-4. PubMed ID: 2569054
[TBL] [Abstract][Full Text] [Related]
22. Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient.
Trimarchi H; Lombi F; Forrester M; Elizondo C; Sawinski D; Pereyra H; Freixas E
Nat Clin Pract Nephrol; 2006 Aug; 2(8):459-63; quiz 464. PubMed ID: 16932480
[TBL] [Abstract][Full Text] [Related]
23. Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure.
Davenport A; Goel S; Mackenzie JC
Scand J Urol Nephrol; 1993; 27(4):447-51. PubMed ID: 8159916
[TBL] [Abstract][Full Text] [Related]
24. The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.
Lee DC; Lee GY
J Toxicol Clin Toxicol; 1998; 36(7):719-21. PubMed ID: 9865241
[TBL] [Abstract][Full Text] [Related]
25. Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial.
Thürlimann B; Waldburger R; Senn HJ; Thiébaud D
Ann Oncol; 1992 Sep; 3(8):619-23. PubMed ID: 1450043
[TBL] [Abstract][Full Text] [Related]
26. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
Major P; Lortholary A; Hon J; Abdi E; Mills G; Menssen HD; Yunus F; Bell R; Body J; Quebe-Fehling E; Seaman J
J Clin Oncol; 2001 Jan; 19(2):558-67. PubMed ID: 11208851
[TBL] [Abstract][Full Text] [Related]
27. Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism.
Tal A; Graves L
South Med J; 1996 Jun; 89(6):637-40. PubMed ID: 8638211
[TBL] [Abstract][Full Text] [Related]
28. [A case of lung cancer with hypercalcemia and renal failure responsive to pamidronate].
Koshida H; Kametani T; Masuda S
Gan To Kagaku Ryoho; 1999 May; 26(6):833-6. PubMed ID: 10410154
[TBL] [Abstract][Full Text] [Related]
29. Hypercalcemia of malignancy.
Body JJ
Semin Nephrol; 2004 Jan; 24(1):48-54. PubMed ID: 14730509
[TBL] [Abstract][Full Text] [Related]
30. Severe Hypercalcemia in a Child With Acute Lymphoblastic Leukemia Relapse: Successful Management With Combination of Calcitonin and Bisphosphonate.
Tagiyev A; Demirbilek H; Tavil B; Buyukyilmaz G; Gumruk F; Cetin M
J Pediatr Hematol Oncol; 2016 Apr; 38(3):232-4. PubMed ID: 26907650
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of hypercalcemia of malignancy with pamidronate in a patient with advanced recurrent oral cancer].
Nishimura N; Matsushita Y; Takaoka K; Hashitani S; Noguchi K; Urade M
Gan To Kagaku Ryoho; 2002 Dec; 29(13):2537-9. PubMed ID: 12506478
[TBL] [Abstract][Full Text] [Related]
32. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
Major P
Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736
[TBL] [Abstract][Full Text] [Related]
33. Safety of pamidronate in patients with renal failure and hypercalcemia.
Machado CE; Flombaum CD
Clin Nephrol; 1996 Mar; 45(3):175-9. PubMed ID: 8706358
[TBL] [Abstract][Full Text] [Related]
34. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
Body JJ; Dumon JC
Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
[TBL] [Abstract][Full Text] [Related]
35. Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia.
Mannix KA; Carmichael J; Harris AL; Cantwell BM
Cancer; 1989 Sep; 64(6):1358-61. PubMed ID: 2766228
[TBL] [Abstract][Full Text] [Related]
36. Current management strategies for hypercalcemia.
Pecherstorfer M; Brenner K; Zojer N
Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
[TBL] [Abstract][Full Text] [Related]
37. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
Major PP; Coleman RE
Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861
[TBL] [Abstract][Full Text] [Related]
38. Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy.
Gallacher SJ; Fraser WD; Logue FC; Dryburgh FJ; Cowan RA; Boyle IT; Ralston SH
Calcif Tissue Int; 1992 Dec; 51(6):419-23. PubMed ID: 1333351
[TBL] [Abstract][Full Text] [Related]
39. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
Gucalp R; Ritch P; Wiernik PH; Sarma PR; Keller A; Richman SP; Tauer K; Neidhart J; Mallette LE; Siegel R
J Clin Oncol; 1992 Jan; 10(1):134-42. PubMed ID: 1727915
[TBL] [Abstract][Full Text] [Related]
40. The use of pamidronate in three children with renal disease.
Sellers E; Sharma A; Rodd C
Pediatr Nephrol; 1998 Nov; 12(9):778-81. PubMed ID: 9874327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]